



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Elezanumab

Cat. No.:	HY-P99359
CAS No.:	1791416-49-3
Target:	TGF-beta/Smad
Pathway:	Stem Cell/Wnt; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC ₅₀ around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism ^{[1][2]} .								
In Vivo	<p>Elezanumab (ABT-555; AE12-1Y-QL; 1-10 mg/kg; IV; once a week for 5 doses) promotes axonal regeneration and prevents retinal nerve fiber layer degeneration in the optic nerve crush and optic neuritis models (female Lewis rats)^[1].</p> <p>Elezanumab (0.01, 0.1, 1, 10 mg/kg; IV; once a week for 3 doses) promotes axonal regeneration and remyelination, decreases inflammatory lesion area and improves functional recovery in the spinal targeted experimental autoimmune encephalomyelitis (EAE) model (female Lewis rats)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female Lewis rat optic neuritis models^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1, 3, or 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IV; once a week for 5 doses</td> </tr> <tr> <td>Result:</td> <td>Protected against the optic nerve inflammationinduced RNFL degeneration. Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg</td> </tr> </table>	Animal Model:	Female Lewis rat optic neuritis models ^[1]	Dosage:	1, 3, or 10 mg/kg	Administration:	IV; once a week for 5 doses	Result:	Protected against the optic nerve inflammationinduced RNFL degeneration. Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg
Animal Model:	Female Lewis rat optic neuritis models ^[1]								
Dosage:	1, 3, or 10 mg/kg								
Administration:	IV; once a week for 5 doses								
Result:	Protected against the optic nerve inflammationinduced RNFL degeneration. Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg								

REFERENCES

- [1]. Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. *Neurobiol Dis.* 2021 Nov;159:105492.
- [2]. Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. *Neurobiol Dis.* 2021 Nov;159:105492.
- [3]. Peer B Jacobson, et al. Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA